IL315865A - Co-crystal forms of a novobiocin analog and proline - Google Patents

Co-crystal forms of a novobiocin analog and proline

Info

Publication number
IL315865A
IL315865A IL315865A IL31586524A IL315865A IL 315865 A IL315865 A IL 315865A IL 315865 A IL315865 A IL 315865A IL 31586524 A IL31586524 A IL 31586524A IL 315865 A IL315865 A IL 315865A
Authority
IL
Israel
Prior art keywords
crystal
proline
solids
disorder
xrpd
Prior art date
Application number
IL315865A
Other languages
English (en)
Hebrew (he)
Inventor
Jiang Xin
Allen WALLING John
J Bevill Melanie
Scott Seadeek Christopher
P Smit Jared
Original Assignee
Reata Pharmaceuticals Inc
Jiang Xin
Allen WALLING John
J Bevill Melanie
Scott Seadeek Christopher
P Smit Jared
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc, Jiang Xin, Allen WALLING John, J Bevill Melanie, Scott Seadeek Christopher, P Smit Jared filed Critical Reata Pharmaceuticals Inc
Publication of IL315865A publication Critical patent/IL315865A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL315865A 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline IL315865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
IL315865A true IL315865A (en) 2024-11-01

Family

ID=65444361

Family Applications (2)

Application Number Title Priority Date Filing Date
IL315865A IL315865A (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline
IL276583A IL276583B2 (en) 2018-02-07 2019-02-01 Crystal structures of proline and a novobiocin analog

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL276583A IL276583B2 (en) 2018-02-07 2019-02-01 Crystal structures of proline and a novobiocin analog

Country Status (19)

Country Link
US (3) US10717755B2 (enExample)
EP (1) EP3749675B1 (enExample)
JP (3) JP2021512910A (enExample)
KR (2) KR20240155354A (enExample)
CN (2) CN112020506B (enExample)
AR (1) AR114245A1 (enExample)
AU (3) AU2019217821B2 (enExample)
BR (1) BR112020016205A2 (enExample)
CA (2) CA3226385A1 (enExample)
CL (2) CL2020002051A1 (enExample)
CO (1) CO2020009761A2 (enExample)
EA (1) EA202091885A1 (enExample)
IL (2) IL315865A (enExample)
MX (2) MX2020008326A (enExample)
MY (1) MY209803A (enExample)
PE (1) PE20211446A1 (enExample)
SG (1) SG11202007530XA (enExample)
TW (3) TWI868593B (enExample)
WO (1) WO2019156907A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512910A (ja) * 2018-02-07 2021-05-20 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011306391B2 (en) * 2010-09-23 2016-12-15 Nuformix Limited Aprepitant L-proline composition and cocrystal
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN104159584A (zh) * 2011-11-25 2014-11-19 诺弗米克斯有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
NZ629778A (en) * 2012-02-09 2016-03-31 Univ Kansas C-terminal hsp90 inhibitors
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CN106536498A (zh) 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
PL3202772T3 (pl) 2014-09-30 2021-02-22 Jiangsu Hengrui Medicine Co. Ltd. Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2
JP2021512910A (ja) 2018-02-07 2021-05-20 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態

Also Published As

Publication number Publication date
IL276583B1 (en) 2024-11-01
SG11202007530XA (en) 2020-09-29
KR20240155354A (ko) 2024-10-28
AU2019217821A1 (en) 2020-09-24
TWI868593B (zh) 2025-01-01
PE20211446A1 (es) 2021-08-05
CN112020506B (zh) 2024-10-11
TWI797249B (zh) 2023-04-01
EA202091885A1 (ru) 2021-01-15
US11401294B2 (en) 2022-08-02
CL2022003784A1 (es) 2023-06-09
MX2020008326A (es) 2020-09-28
CN118894894A (zh) 2024-11-05
AR114245A1 (es) 2020-08-12
JP2026012851A (ja) 2026-01-27
CO2020009761A2 (es) 2020-10-30
TW202510893A (zh) 2025-03-16
NZ767558A (en) 2024-11-29
MY209803A (en) 2025-08-05
US20190241599A1 (en) 2019-08-08
IL276583A (en) 2020-09-30
US20200347088A1 (en) 2020-11-05
MX2022012856A (es) 2022-11-30
TW201945381A (zh) 2019-12-01
AU2024227646A1 (en) 2024-11-14
CA3090646A1 (en) 2019-08-15
EP3749675B1 (en) 2025-12-31
CA3090646C (en) 2024-02-27
US20240043465A1 (en) 2024-02-08
AU2022283638A1 (en) 2023-02-02
CL2020002051A1 (es) 2021-02-19
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CA3226385A1 (en) 2019-08-15
EP3749675A1 (en) 2020-12-16
WO2019156907A1 (en) 2019-08-15
JP2024001167A (ja) 2024-01-09
AU2022283638B2 (en) 2024-07-25
US10717755B2 (en) 2020-07-21
TWI915111B (zh) 2026-02-11
BR112020016205A2 (pt) 2020-12-15
AU2019217821B2 (en) 2022-09-08
IL276583B2 (en) 2025-03-01
JP2021512910A (ja) 2021-05-20
CN112020506A (zh) 2020-12-01
KR102718111B1 (ko) 2024-10-17

Similar Documents

Publication Publication Date Title
AU2022283638B2 (en) Co-crystal forms of a novobiocin analog and proline
US20240300961A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
IL272190B (en) Inhibitors of gamma ror
HUE030930T2 (hu) Az N-(3-(4-(3-(diizobutilamino)-propil)-piperazin-l-il)-propil)-lH-benzo[d]imidazol-2-amin szulfát sói, eljárás azok elõállítására és alkalmazásuk
IL284564B2 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
US20210121422A1 (en) Glucagon receptor antagonists
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
IL295992A (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
IL315658A (en) Levodopa tyrosine polymorphs
EA052030B1 (ru) Тип соли и кристаллическая форма ингибитора фактора b комплемента, способ их получения и их применение